Articles tagged "Rejection"

2016 American Transplant Congress
Kidney Transplant Recipient Adherence Measured by Proportion of Days Covered Is Associated with Late Biopsy Proven Acute Rejection.
B. Hofmeyer, K. Look, J. Fose, A. Pulvermacher, A. Djamali, D. Hager.
UW Health, Madison, WI.
While medication non-adherence is a known risk factor for late “biopsy proven acute rejection (BPAR),” the Pharmacy Quality Alliance definition of “proportion of days covered…
2016 American Transplant Congress
Fecal Microbiota Transplant Results in Durable Changes to Host Microbiota That Correlate with Allograft Outcome.
C. Brinkman, L. Hittle, W. Fricke, E. Mongodin, J. Bromberg.
CVID and IGS, University of Maryland School of Medicine, Baltimore, MD.
Hypothesis: We previously presented highly significant differences in the bacterial community structures of human renal allograft recipients over time. Likewise, murine normal, colitic, and pregnant…
2016 American Transplant Congress
Profiling Immunologic Risk for Acute Rejection in Liver Transplantation: Recipient Age Is a Robust Risk Factor.
M. Kueht, R. Cotton, C. O'Mahony, J. Goss, A. Rana.
Surgery, Division of Abdominal Transplantation and Hepatobiliary Surgery, Balyor College of Medicine, Houston, TX.
Profiling the immunologic risk for acute rejection in liver transplantation (OLT) may allow for selection immunosuppression (IS) target ranges appropriate to risk levels, all with…
2016 American Transplant Congress
Effect of Complement Inhibition Therapy (Eculizumab) in Patients with C1q-Binding Donor-Specific Anti-HLA Antibodies: A Molecular Appraisal.
C. Lefaucheur,¹ L. Hidalgo,² J. Reeve,² D. Viglietti,¹ C. Gosset,¹ O. Aubert,³ C. Ulloa,³ C. Legendre,³ D. Glotz,¹ P. Halloran,² A. Loupy.³
¹Saint-Louis Hospital, Paris, France; ²University of Alberta, Edmonton, Canada; ³Necker Hospital, Paris, France.
Complement-binding anti-HLA DSA have demonstrated higher rejection rate and decreased allograft outcome. We investigated the effect of terminal complement inhibition (Eculizumab) in a cohort of…
2016 American Transplant Congress
Detecting Renal Allograft Inflammation Using Quantitative Urine Metabolomics and CXCL10.
J. Ho,¹ A. Sharma,² R. Mandal,³ D. Wishart,³ C. Wiebe,¹ L. Storsley,¹ M. Karpinski,¹ I. Gibson,⁴ P. Nickerson,¹ D. Rush.¹
¹Internal Medicine, University of Manitoba, Winnipeg, MB, Canada; ²Pediatrics & Child Health, University of Manitoba, Winnipeg, MB, Canada; ³Biological Sciences, University of Alberta, Edmonton, AB, Canada; ⁴Pathology, University of Manitoba, Winnipeg, MB, Canada.
Background. We studied urine metabolomics (UM) alone or combined with urine CXCL10 to non-invasively detect cellular infiltrates in renal allograft biopsies.Methods. Urines (n=137) were obtained…
2016 American Transplant Congress
Bortezomib Impacts Tenascin mRNA in PBMNCs.
E. Bradley, O. Moussa, K. Twombley.
Medical University of South Carolina, Charleston.
Tenascin (TNC) is a gene thought to play a role in the binding of receptors and syndecan binding. Syndecans are signal transmembrane proteins that act…
2016 American Transplant Congress
Clinical Impact of Pre-Transplant Serum 25-Hydroxyvitamin D Levels on the Post-Transplant Immunologic and Non-Immunologic Outcomes in Kidney Transplant Recipients.
T. Ban,^1,2 J. Kim,^1,2 Y. Lee,¹ B. Choi,^1,2 C. Park,^1,2 C. Yang,^1,2 Y.-S. Kim,^1,2 B. Chung.^1,2
¹Division of Nephrology, Department of Internal Medicine, Seoul St. Mary's Hospital, Seoul, Korea; ²Transplant Research Center, Seoul St. Mary's Hospital, Seoul, Korea.
Background: The aim of this study is to investigate the clinical significance of pre-transplant serum 25-hydroxyvitamin D (25(OH)D) levels in regard to post-transplant clinical outcome…
2016 American Transplant Congress
Impact of Preformed Anti-HLA Antibodies in the Outcomes of Kidney Transplantation.
S. Santos,¹ J. Malheiro,¹ M. Costa,² A. Campos,¹ S. Pedroso,¹ M. Almeida,¹ L. Martins,¹ L. Dias,¹ C. Henriques,¹ A. Cabrita.¹
¹Nephrology, Hospital Santo António, CHP, Porto, Portugal; ²Nephrology, Centro Hospitalar Tondela-Viseu, Viseu, Portugal.
Background:Anti-HLA antibodies are risk factors for acute and chronic rejection and allograft loss. Its detection represents a major advance and is widely used in organ…
2016 American Transplant Congress
Anti-HLA Antibody Composition and Outcomes in Pediatric Heart Transplant Recipients with a Positive Cross-Match.
P. Jindra,¹ S. Nicholas,² J. Chappelle,¹ T. Humlicek,² K. Hosek,² J. Heinle,² S. Denfield,² A. Jeewa,² R. Kerman,¹ W. Dreyer.²
¹Surgery Immune Evaluation Lab, Baylor College of Medicine, Houston, TX; ²Pediatrics, Baylor College of Medicine, Houston, TX.
Purpose: Utilization of positive (+) cross-match (XM) hearts is tempting when shortages of pediatric donor hearts exist, especially for patients with high pre-transplant panel reactive…
2016 American Transplant Congress
Risk of Acute Rejection Among ABO Incompatible Living Donor Kidney Recipients.
P. MacLennan, V. Kumar, R. Reed, D. Mompoint-Williams, K. Stegner, J. Locke.
School of Medicine, University of Alabama at Birmingham, Birmingham, AL.
Background: ABO incompatible (ABOi) live donor kidney transplantation (LDKT) holds the potential for increased access to transplantation for ESRD patients. Concerns remain related to the…